FDA Announces Recall of Apple Juice in 28 States Due to Potential Mold Contamination
According to the U.S. Food and Drug Administration (FDA), 7,234 cases of Martinelli's apple juice are subject to recall due to potential mold contamination.
A single lot of 10-ounce glass bottles of Martinelli's Apple Juice (sold in four-packs) may contain elevated levels of patulin, a naturally occurring mycotoxin produced by mold and fungus that may be present in apples. Long-term exposure to patulin can cause nausea, gastrointestinal issues, vomiting, and other side effects.
While S. Martinelli & Company originally issued the voluntary recall on March 18, the FDA posted the Class II classification notice on April 22. A Class II recall is the second most severe type of recall, indicating that the product may cause "temporary" or "reversible" health consequences.
The recalled juice was sold in four-packs of round, clear glass 10-ounce bottles with white metal screw top lids. It can be further identified with the following information:
UPC: 0 41244 04102 2
Best By Date: Dec. 5, 2026
Affected cases were distributed to stores in 28 states: Alabama, Arkansas, Arizona, California, Connecticut, Delaware, Florida, Georgia, Iowa, Illinois, Indiana, Kansas, Kentucky, Louisiana, Michigan, Missouri, Mississippi, North Carolina, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, South Carolina, Texas, Utah, Virginia, and Wisconsin.
A full list of pallet/batch numbers can be found on the FDA recall notice page.
While the FDA doesn't list specific instructions, it is typically advised that if you have the recalled Martinelli's Apple Juice, you should not consume it. Instead, dispose of it or return it to the original place of purchase for a refund. Contact your healthcare provider if you have additional concerns regarding patulin exposure.
Consumers with questions about the recall can contact S. Martinelli at 1-800-622-1868.Popular Costco Product Recalled for Wood Contamination
USDA Announces Health Alert for Pork Sold at Aldi Due to Potential Metal Contamination
USDA Issues Health Alert for Multiple Brands of Soup—Including Campbell's—for Potential Wood ContaminationRead the original article on ALLRECIPES
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Trump admin approves waivers for 3 states to ban soda, other junk food from public food programs
Department of Agriculture Secretary Brooke Rollins signed waivers with three states on Tuesday, allowing them to prohibit participants of the government's Supplemental Nutrition Assistance Program (SNAP) from buying junk food, like soda and candy, through the social welfare program. Arkansas, Idaho and Utah became the latest states to obtain waivers from the federal government to begin banning junk food within the federally administered, but state-operated, public assistance program that provides food stamps to low-income individuals. The three states have become the latest to obtain waivers from the Trump administration that allow states to restrict what type of food SNAP funds are eligible to be used on. Other mostly GOP-led states, like Nebraska, Indiana and Iowa, have also obtained waivers to reform their SNAP programs. Last month, during a Make America Healthy Again (MAHA) event at the White House, Rollins indicated that several states were lining up to get the waivers. Nebraska Becomes First State Approved To Ban Soda Purchases With Food Stamps "Since my confirmation, [the U.S. Department of Agriculture (USDA)] has encouraged states to think differently and creatively about how to solve the many health issues facing Americans," Rollins said at a press conference announcing the new waivers Tuesday afternoon. "One way is disallowing taxpayer-funded benefits to purchase unhealthy items, like soda, candy and other junk food." Read On The Fox News App Tuesday's waivers bring the total number of states that have moved to ban junk food from their SNAP programs to six. Rollins indicated several other states, including Colorado, Kansas, West Virginia, Texas, Ohio, Florida and Louisiana, are also working through procedural steps in hopes of getting waivers approved. West Virginia Passes First-of-its-kind Law Banning Food Dyes And Preservatives; Gov Cites Maha Movement Texas, however, may not even need the waiver after its legislature passed Senate Bill 379 during the last week of its legislative session that ended on June 2. The new bill, which prohibits SNAP participants in the state from using the public assistance program to buy junk food, is expected to be signed by Republican Gov. Greg Abbott, especially after he wrote a letter to Rollins in May seeking a USDA waiver. "The Trump Administration is unified in improving the health of our nation. America's governors have proudly answered the call to innovate by improving nutrition programs, ensuring better choices while respecting the generosity of the American taxpayer," Rollins added Tuesday. "Each waiver submitted by the states and signed is yet another step closer to fulfilling President [Donald] Trump's promise to Make America Healthy Again." On average, 42 million low-income Americans receive food-stamp assistance each month, according to the MAHA report released last month. It added that one-in-five American children under 17 receive SNAP article source: Trump admin approves waivers for 3 states to ban soda, other junk food from public food programs
Business Insider
3 hours ago
- Business Insider
Argenx presents new Efgartigimod data at EULAR 2025
argenx (ARGX) SE 'announced the presentation of positive results from Phase 2 studies evaluating VYVGART in Sjogren's disease and idiopathic inflammatory myopathies at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the FDA has granted efgartigimod Fast Track designation for the treatment of primary Sjogren's disease.' Confident Investing Starts Here: Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
3 hours ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
